Francisco G. La Rosa, MD, presented “Second Opinion Diagnosis in Prostate Pathology” during the 29th Annual International Prostate Cancer Update on January 26, 2019 in Beaver Creek, Colorado.
How to cite: La Rosa, Francisco G. “Second Opinion Diagnosis in Prostate Pathology” January 26, 2019. Accessed Nov 2024. https://dev.grandroundsinurology.com/second-opinion-diagnosis-in-prostate-pathology/
Second Opinion Diagnosis in Prostate Pathology
Francisco G. La Rosa, MD, discusses how poor preparation of biopsy and prostatectomy specimens, as well as pathologists’ misreadings, can lead to significant discrepancies in the diagnosis of prostate cancer. He emphasizes the importance of reevaluation by in-house urologic pathologists of all outside specimens before evaluating treatment options for patients.
Abstract:
Prostate cancer (PCa) is one of the most common male diseases in the USA. The gold standard for PCa diagnosis is based on a careful and comprehensive histopathologic examination of prostatic tissue to deliver allied specialty colleagues with the correct information. This allows them to tailor the most appropriate therapeutic procedures to individual patients.
An accurate diagnosis is not only based on the expertise of the pathologists recognizing PCa under the microscope, but also on the support of a proficient histology laboratory with enough experience in the preparation of biopsies and prostatectomy specimens.
Pathologists need to keep updated in the constant changes in PCa classification and in the evaluation of other specific tumor features. They also need to maintain a permanent and close professional collaboration with their clinical, oncology, and surgical colleagues to construct sound clinical-pathological correlations that can secure the right care for their patients.
An accurate pathology diagnosis relies on a precise evaluation of tumor grading, together with important features such as perineural invasion, extraprostatic extension, lymphovascular invasion, surgical margins, invasion of seminal vesicles, therapy effect, etc., as well as the assessment of metastatic disease in lymph nodes and other organs. This is in conjunction with the implementation of special histological stainings for the proper identification of PCa. In many cases, due to poor histopathological preparations and the pathologist’s lack of proficiency, we find significant discrepancies in the diagnosis of PCa that may lead to inadequate therapeutic procedures.
We have found significant discrepancies between general pathologists outside our institution and our in-house pathologists [1], with the most important discrepancies involving tumor undergrading predominating above overgrading, and in the differentiation between primary and secondary PCa grades. Outside pathologists also failed to report important features relevant to the patient’s prognosis, such as perineural invasion, extraprostatic extension, and surgical margins.
Since histopathological evaluation is a critical factor for appropriate treatment selection, we recommend that a reevaluation by in-house urologic pathologists should be performed in all outside specimens before patients are evaluated for treatment in any given institution.
About the International Prostate Cancer Update
The International Prostate Cancer Update (IPCU) is an annual, multi-day CME conference focused on prostate cancer treatment updates. The conference’s faculty consists of international experts, and the event caters to urologists, medical oncologists, radiation oncologists, and other healthcare professionals. Topics encompass prostate cancer management, from diagnosis to treating advanced and metastatic disease. Dr. La Rosa presented this lecture during the 29th IPCU in 2019. Please visit this page in order to learn more about future IPCU meetings.
ABOUT THE AUTHOR
Francisco G. La Rosa, MD, is an Associate Professor in the Department of Pathology at the University of Colorado Anschutz Medical Campus in Denver. He is also a member of the University of Colorado Cancer Center. He is an active clinician, researcher, and teacher, and is board-certified in anatomic and clinical pathology. Additionally, Dr. La Rosa specializes in genitourinary, renal, and heart pathology, and is an expert in pathology informatics. Dr. La Rosa has more than 90 publications in peer-reviewed journals. He is an active member of many national and international organizations, including the College of American Pathologists, the American Urological Association, the Catholic Medical Association, the American Telemedicine Association, Asociación Iberoamericana de Teleslud y Telemedicina, and the Peruvian American Medical Association. As an investigator in genitourinary pathology, he is a member and study coordinator for the Southwest Oncology Group (SWOG) Genitourinary Committee, and a collaborator with the research groups led by Drs. E. David Crawford and Thomas W. Flaig in innovative technology for the diagnosis and treatment of prostate and urinary cancer.
